Akron Bio Expands Commercialization of Gene Therapy and Vaccine Production with New Manufacturing Facility
Akron Bio has launched a new, state-of-the-art cGMP plasmid DNA manufacturing facility in Sarasota, Florida to address critical demands in the rapidly growing gene therapy and vaccine markets.
Through the new facility, Akron Bio will provide plasmid DNA, critical material used in the production of advanced therapies. The new site will support an increasing clinical development pipeline by relieving and securing industry supply. Akron Bio continues to set industry standards, in collaboration with global standard organizations and therapeutic providers, to ensure consistency, efficacy and safety of these advanced therapies.
Akron Bio selected Manatee County for its new facility location because of the rapidly emerging biomedical hub in the region as well as the support of local and state government. As part of its expansion, Akron Bio will double its Sarasota workforce to more than 100 by the end of 2022, with plans to expand in the future to meet the growing customer demand.
About Akron Bio
Akron Bio is a materials manufacturer and services provider to the regenerative medicine industry. Akron’s Boca facility is ISO 13485-certified operating in line with cGMP guidelines and international standards, Akron Bio leverages more than 100,000 square feet of development and manufacturing capacity to provide advanced therapy developers the scale, compliance and regulatory support necessary to drive novel treatments from discovery to commercialization. More information is available at www.akronbiotech.com.